BridgeBio Pharma Inc Aktie News

BridgeBio Pharma, Inc. ( BBIO ) UBS Global Healthcare Conference 2025 November 10, 2025 1:15 PM EST Company Participants Chinmay Shukla Ananth Sridhar - Chief Operating Officer of Cardiorenal Anna Wade Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division Good day, everybody. My name is Ash Verma.

- Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated: 59% risk reduction in ACM in the ATTR-CM variant population at Month 42 (p=0.032) compared to patients initially randomized to placebo in the ATTRibute-CM study 69% risk reduction in ACM/ first CVH through Month 30 compared to placebo (p=0.016) and a 69% risk reduction in ACM through Mont...

Following a challenge submitted by Pfizer, Inc., BBB National Programs' National Advertising Division will refer BridgeBio Pharma Inc. to the relevant government agencies for review and possible enforcement action for failure to participate in the National Advertising Division (NAD) inquiry. Following a challenge submitted by Pfizer, Inc., BBB National Programs' National Advertising Division wi...

PALO ALTO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host fireside chats at the following healthcare investor conferences:

The volatile sector is seeing greater stability, and these four stocks can profit.

PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that ten moderated digital posters will be shared at the American Heart Association (AHA) Scientific Sessions 2025, taking place in New Orleans, LA from November 7 - 10, 2025.

BBIO's Attruby (Acoramidis) delivers early, durable reductions in cumulative cardiovascular events. This candidate positions BBIO against Pfizer's Tafamidis and Alnylam's Amvuttra. Its US uptake keeps growing since November 2024. BBIO's pipeline also has catalysts with BBP-418 and Encaleret. These NDAs are planned for 1H2026.

BridgeBio Pharma, Inc. ( BBIO ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Chinmay Shukla Neil Kumar - Co-Founder, CEO & Director Matthew Outten - Chief Commercial Officer Thomas Trimarchi - CFO & President Conference Call Participants Salim Syed - Mizuho Securities USA LLC, Research Division Tyler Van Buren - TD Cowen, Research Division Biren Amin - Piper Sandler &...